David Henry's JCSO Podcast

For the March-April issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, discusses two informative “how-to” articles, one on the implementation of a distress management program at an oncology hospital in Puerto Rico, the other on the prevention and treatment options for mTOR inhibitor-associated stomatitis. Dr Henry also shares his preferences for addressing health care reform, and he highlights a letter to the journal in response to the January-February issue Commentary on physician-assisted dying. Immunotherapies are at the fore again, this time with an insightful essay by Jane de Lartigue who writes that combination therapy is likely to be key in expanding the scope of immunotherapy into currently unresponsive patient populations, which raises questions about the optimal combinations and the timing and sequencing of combination immunotherapy. Three Original Reports span the clinical, supportive, and quality- and value-based care components of cancer care, with their respective foci on APF530 for nausea and vomiting prevention after cisplatin; patterns of care in whole-brain radiotherapy technique and delivery; and emergency department use by newly diagnosed cancer patients. As usual, there is a line-up of rare and challenging presentations in Case Reports on pulmonary sarcomatoid carcinoma presenting as a necrotizing cavitary lung lesions, palmoplantar exacerbation of psoriasis after nivolumab for lung cancer, primary cardiac prosthetic valve-associated lymphoma; and atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia.

Listen to the podcast below.

For the March-April issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, discusses two informative “how-to” articles, one on the implementation of a distress management program at an oncology hospital in Puerto Rico, the other on the prevention and treatment options for mTOR inhibitor-associated stomatitis. Dr Henry also shares his preferences for addressing health care reform, and he highlights a letter to the journal in response to the January-February issue Commentary on physician-assisted dying. Immunotherapies are at the fore again, this time with an insightful essay by Jane de Lartigue who writes that combination therapy is likely to be key in expanding the scope of immunotherapy into currently unresponsive patient populations, which raises questions about the optimal combinations and the timing and sequencing of combination immunotherapy. Three Original Reports span the clinical, supportive, and quality- and value-based care components of cancer care, with their respective foci on APF530 for nausea and vomiting prevention after cisplatin; patterns of care in whole-brain radiotherapy technique and delivery; and emergency department use by newly diagnosed cancer patients. As usual, there is a line-up of rare and challenging presentations in Case Reports on pulmonary sarcomatoid carcinoma presenting as a necrotizing cavitary lung lesions, palmoplantar exacerbation of psoriasis after nivolumab for lung cancer, primary cardiac prosthetic valve-associated lymphoma; and atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia.

Listen to the podcast below.

For the March-April issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, discusses two informative “how-to” articles, one on the implementation of a distress management program at an oncology hospital in Puerto Rico, the other on the prevention and treatment options for mTOR inhibitor-associated stomatitis. Dr Henry also shares his preferences for addressing health care reform, and he highlights a letter to the journal in response to the January-February issue Commentary on physician-assisted dying. Immunotherapies are at the fore again, this time with an insightful essay by Jane de Lartigue who writes that combination therapy is likely to be key in expanding the scope of immunotherapy into currently unresponsive patient populations, which raises questions about the optimal combinations and the timing and sequencing of combination immunotherapy. Three Original Reports span the clinical, supportive, and quality- and value-based care components of cancer care, with their respective foci on APF530 for nausea and vomiting prevention after cisplatin; patterns of care in whole-brain radiotherapy technique and delivery; and emergency department use by newly diagnosed cancer patients. As usual, there is a line-up of rare and challenging presentations in Case Reports on pulmonary sarcomatoid carcinoma presenting as a necrotizing cavitary lung lesions, palmoplantar exacerbation of psoriasis after nivolumab for lung cancer, primary cardiac prosthetic valve-associated lymphoma; and atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia.

Listen to the podcast below.

For the January-February issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, highlights a thought-provoking article by JCSO Editor, Dr Thomas Strouse, on end-of-life options and legal pathways to physician-assisted dying. He also features a guide by Dr Adam Bagg on the diagnosis and classification of lymphomas, and an in-depth examination of blood-based biopsies by Jane de Lartigue. Three Original Reports hone in on patient care and support and quality of care: a report on the Florida CaPCaS study documents the experiences and needs of black men at the point of prostate cancer diagnosis; another, among Spanish-speaking Latinas with breast cancer, addresses the posttreatment survivorship care needs of that population; and a third looks at strategies to improve the quality of care among head and neck cancer patients. Among the Journal’s regular offerings, the Community Translations section features the approvals of atezolizumab as a therapy for bladder cancer (the first in more than 30 years) and lenvatinib for renal cell carcinoma, and there are two Case Report, one on a patient with breast cancer who experienced severe hyponatremia with seizures associated with single-, low-dose cyclophosphamide, and another about paraneoplastic leukemoid reaction as a poor prognostic marker in a patient with urothelial bladder carcinoma.

Listen to the podcast below.

For the January-February issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, highlights a thought-provoking article by JCSO Editor, Dr Thomas Strouse, on end-of-life options and legal pathways to physician-assisted dying. He also features a guide by Dr Adam Bagg on the diagnosis and classification of lymphomas, and an in-depth examination of blood-based biopsies by Jane de Lartigue. Three Original Reports hone in on patient care and support and quality of care: a report on the Florida CaPCaS study documents the experiences and needs of black men at the point of prostate cancer diagnosis; another, among Spanish-speaking Latinas with breast cancer, addresses the posttreatment survivorship care needs of that population; and a third looks at strategies to improve the quality of care among head and neck cancer patients. Among the Journal’s regular offerings, the Community Translations section features the approvals of atezolizumab as a therapy for bladder cancer (the first in more than 30 years) and lenvatinib for renal cell carcinoma, and there are two Case Report, one on a patient with breast cancer who experienced severe hyponatremia with seizures associated with single-, low-dose cyclophosphamide, and another about paraneoplastic leukemoid reaction as a poor prognostic marker in a patient with urothelial bladder carcinoma.

Listen to the podcast below.

For the January-February issue of the Journal of Community and Supportive Oncology, the Editor in Chief, Dr David Henry, highlights a thought-provoking article by JCSO Editor, Dr Thomas Strouse, on end-of-life options and legal pathways to physician-assisted dying. He also features a guide by Dr Adam Bagg on the diagnosis and classification of lymphomas, and an in-depth examination of blood-based biopsies by Jane de Lartigue. Three Original Reports hone in on patient care and support and quality of care: a report on the Florida CaPCaS study documents the experiences and needs of black men at the point of prostate cancer diagnosis; another, among Spanish-speaking Latinas with breast cancer, addresses the posttreatment survivorship care needs of that population; and a third looks at strategies to improve the quality of care among head and neck cancer patients. Among the Journal’s regular offerings, the Community Translations section features the approvals of atezolizumab as a therapy for bladder cancer (the first in more than 30 years) and lenvatinib for renal cell carcinoma, and there are two Case Report, one on a patient with breast cancer who experienced severe hyponatremia with seizures associated with single-, low-dose cyclophosphamide, and another about paraneoplastic leukemoid reaction as a poor prognostic marker in a patient with urothelial bladder carcinoma.

Listen to the podcast below.

In the December podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a round-up and review by Linda Bosserman, an Editor on the Journal, of the 2016 oncology landscape – from new therapy approvals, to practice pathways and value-based care, and the implementation of MACRA. Also included are Original Reports on patients’ retrospective assessment of palliative chemotherapy for lung or gastrointestinal cancers, social support needs among patients with advanced breast cancer, and quality of life after surgery for pleural malignant mesothelioma. As always, we focus on cutting edge care for the cancer patient, with two features, one by our regular contributor, Jane de Lartigue, who brings us up to date on new therapies for pancreatic cancer, and a second, practice-oriented article that reports on adopting a team approach for co-managing the clinical and palliative components in caring for our patients. Among the regular offerings, we have Case Reports on paraneoplastic Isaacs syndrome that led to diagnosis of small-cell lung cancer and unicentric Castleman disease that was disguised as a pancreatic neoplasm, and a Community Translations report on the approval of pembrolizumab as the first immune checkpoint inhibitor to receive approval for head and neck cancer.

Listen to the podcast below.

In the December podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a round-up and review by Linda Bosserman, an Editor on the Journal, of the 2016 oncology landscape – from new therapy approvals, to practice pathways and value-based care, and the implementation of MACRA. Also included are Original Reports on patients’ retrospective assessment of palliative chemotherapy for lung or gastrointestinal cancers, social support needs among patients with advanced breast cancer, and quality of life after surgery for pleural malignant mesothelioma. As always, we focus on cutting edge care for the cancer patient, with two features, one by our regular contributor, Jane de Lartigue, who brings us up to date on new therapies for pancreatic cancer, and a second, practice-oriented article that reports on adopting a team approach for co-managing the clinical and palliative components in caring for our patients. Among the regular offerings, we have Case Reports on paraneoplastic Isaacs syndrome that led to diagnosis of small-cell lung cancer and unicentric Castleman disease that was disguised as a pancreatic neoplasm, and a Community Translations report on the approval of pembrolizumab as the first immune checkpoint inhibitor to receive approval for head and neck cancer.

Listen to the podcast below.

In the December podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a round-up and review by Linda Bosserman, an Editor on the Journal, of the 2016 oncology landscape – from new therapy approvals, to practice pathways and value-based care, and the implementation of MACRA. Also included are Original Reports on patients’ retrospective assessment of palliative chemotherapy for lung or gastrointestinal cancers, social support needs among patients with advanced breast cancer, and quality of life after surgery for pleural malignant mesothelioma. As always, we focus on cutting edge care for the cancer patient, with two features, one by our regular contributor, Jane de Lartigue, who brings us up to date on new therapies for pancreatic cancer, and a second, practice-oriented article that reports on adopting a team approach for co-managing the clinical and palliative components in caring for our patients. Among the regular offerings, we have Case Reports on paraneoplastic Isaacs syndrome that led to diagnosis of small-cell lung cancer and unicentric Castleman disease that was disguised as a pancreatic neoplasm, and a Community Translations report on the approval of pembrolizumab as the first immune checkpoint inhibitor to receive approval for head and neck cancer.

Listen to the podcast below.

In the November podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, presents an in-depth interview on myelodysplastic syndromes that he conducted with Dr David Steensma of the Dana-Farber Cancer Institute in Boston as well as a number of articles that focus on hematologic malignancies. The latter include Original Reports on using split-dose R-CHOP to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCL and on outcomes of tumor lysis syndrome in pediatric patients with hematologic malignancies, a Case Report on acute-onset hypokalemic paralysis with arsenic trioxide therapy in patient with acute promyelocytic leukemia, and a Community Translations report on the approval of ofatumumab for patients with chronic lymphocytic leukemia. Also in the line-up are a review by JCSO Editor, Dr David Cella, about value-based cancer care from the patient perspective, and articles on multidisciplinary treatment planning in elderly patients with cancer and palliative concurrent chemoradiation for gastrostomy site metastasis.

Listen to the podcast below.

In the November podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, presents an in-depth interview on myelodysplastic syndromes that he conducted with Dr David Steensma of the Dana-Farber Cancer Institute in Boston as well as a number of articles that focus on hematologic malignancies. The latter include Original Reports on using split-dose R-CHOP to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCL and on outcomes of tumor lysis syndrome in pediatric patients with hematologic malignancies, a Case Report on acute-onset hypokalemic paralysis with arsenic trioxide therapy in patient with acute promyelocytic leukemia, and a Community Translations report on the approval of ofatumumab for patients with chronic lymphocytic leukemia. Also in the line-up are a review by JCSO Editor, Dr David Cella, about value-based cancer care from the patient perspective, and articles on multidisciplinary treatment planning in elderly patients with cancer and palliative concurrent chemoradiation for gastrostomy site metastasis.

Listen to the podcast below.

In the November podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, presents an in-depth interview on myelodysplastic syndromes that he conducted with Dr David Steensma of the Dana-Farber Cancer Institute in Boston as well as a number of articles that focus on hematologic malignancies. The latter include Original Reports on using split-dose R-CHOP to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCL and on outcomes of tumor lysis syndrome in pediatric patients with hematologic malignancies, a Case Report on acute-onset hypokalemic paralysis with arsenic trioxide therapy in patient with acute promyelocytic leukemia, and a Community Translations report on the approval of ofatumumab for patients with chronic lymphocytic leukemia. Also in the line-up are a review by JCSO Editor, Dr David Cella, about value-based cancer care from the patient perspective, and articles on multidisciplinary treatment planning in elderly patients with cancer and palliative concurrent chemoradiation for gastrostomy site metastasis.

Listen to the podcast below.

In the October podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, discusses Original Reports on toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers and on the impact of a literacy-sensitive intervention on CRC screening knowledge, attitudes, and intention to screen as well as an editorial by JCSO Editor Jame Abraham on lessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancer. Also up for discussion are the approval of cabozantinib for renal cell carcinoma, and two Case Reports on central nervous system manifestations of multiple myeloma and on primary chest-wall leiomyosarcoma. Rounding out the discussion are two featured articles, one on new therapies for urologic cancers and another on a step-by-step guide for doctors who want to take to the Twittersphere.

Listen to the podcast below.

In the October podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, discusses Original Reports on toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers and on the impact of a literacy-sensitive intervention on CRC screening knowledge, attitudes, and intention to screen as well as an editorial by JCSO Editor Jame Abraham on lessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancer. Also up for discussion are the approval of cabozantinib for renal cell carcinoma, and two Case Reports on central nervous system manifestations of multiple myeloma and on primary chest-wall leiomyosarcoma. Rounding out the discussion are two featured articles, one on new therapies for urologic cancers and another on a step-by-step guide for doctors who want to take to the Twittersphere.

Listen to the podcast below.

In the October podcast for The Journal of Community and Supportive Oncology, the Editor-in-Chief, Dr David Henry, discusses Original Reports on toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers and on the impact of a literacy-sensitive intervention on CRC screening knowledge, attitudes, and intention to screen as well as an editorial by JCSO Editor Jame Abraham on lessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancer. Also up for discussion are the approval of cabozantinib for renal cell carcinoma, and two Case Reports on central nervous system manifestations of multiple myeloma and on primary chest-wall leiomyosarcoma. Rounding out the discussion are two featured articles, one on new therapies for urologic cancers and another on a step-by-step guide for doctors who want to take to the Twittersphere.

Listen to the podcast below.

In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.

Listen to the podcast below.

In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.

Listen to the podcast below.

In the August podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses recent approvals by the Food and Drug Administration – for uridine triacetate as an antidote for 5-fluorouracil overdose and toxicity, and for two therapies for multiple myeloma, the monoclonal antibody elotuzumab and the proteasome inhibitor ixazomib. Also in this month’s line-up are study findings on abnormal vaginal bleeding and contraception counseling in women who are undergoing chemotherapy; the effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia; and on mindfulness-based cancer recovery in survivors recovering from chemotherapy and radiation. Two Case Reports focus on gastrointestinal cancers, one in a patients with high-grade leiomyosarcoma of the transverse colon and who presented with bowel perforation, and another on 1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST, and the New Therapies feature provides a detailed examination of recent advances in managing gynecologic cancers.

Listen to the podcast below.

In the July podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an editorial by Dr Linda bosserman, in which she presents the case for pathways and the importance of processes and team work in paving the way for value-based care. Survivor care is the focus of 2 Original Reports in which investigators report on adolescent and young adult perceptions of cancer survivor care and supportive programming and on the symptoms, unmet need, and quality of life among recent breast cancer survivors. Also in the Original Report section are reports on the impact of loss of income and medicine costs on the financial burden for cancer patients in Australia and the use of a gene-panel for testing for hereditary ovarian cancer. Dr Henry also looks at 2 Case Reports, one in which a patient undergoes multivisceral resection for growing teratoma syndrome and another in which a patient presents with aleukemic acute lymphoblastic leukemia with unusual clinical features. Diabetes management in cancer patients is the topic of a lengthy and informative interview between Dr Henry and Dr Todd Brown.

Listen to the podcast below.

In the July podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an editorial by Dr Linda bosserman, in which she presents the case for pathways and the importance of processes and team work in paving the way for value-based care. Survivor care is the focus of 2 Original Reports in which investigators report on adolescent and young adult perceptions of cancer survivor care and supportive programming and on the symptoms, unmet need, and quality of life among recent breast cancer survivors. Also in the Original Report section are reports on the impact of loss of income and medicine costs on the financial burden for cancer patients in Australia and the use of a gene-panel for testing for hereditary ovarian cancer. Dr Henry also looks at 2 Case Reports, one in which a patient undergoes multivisceral resection for growing teratoma syndrome and another in which a patient presents with aleukemic acute lymphoblastic leukemia with unusual clinical features. Diabetes management in cancer patients is the topic of a lengthy and informative interview between Dr Henry and Dr Todd Brown.

Listen to the podcast below.

In the July podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses an editorial by Dr Linda bosserman, in which she presents the case for pathways and the importance of processes and team work in paving the way for value-based care. Survivor care is the focus of 2 Original Reports in which investigators report on adolescent and young adult perceptions of cancer survivor care and supportive programming and on the symptoms, unmet need, and quality of life among recent breast cancer survivors. Also in the Original Report section are reports on the impact of loss of income and medicine costs on the financial burden for cancer patients in Australia and the use of a gene-panel for testing for hereditary ovarian cancer. Dr Henry also looks at 2 Case Reports, one in which a patient undergoes multivisceral resection for growing teratoma syndrome and another in which a patient presents with aleukemic acute lymphoblastic leukemia with unusual clinical features. Diabetes management in cancer patients is the topic of a lengthy and informative interview between Dr Henry and Dr Todd Brown.

Listen to the podcast below.

In the June podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses the approval of alectinib as a new option for ALK-positive patients with NSCLC who have progressed on crizotinib, and a How We Do It article in which the authors the implementation of ipilimumab therapy in a private practice oncology group. The authors describe how they addressed start-up and reimbursement issues related to ipilimumab as a model for other expensive new cancer drugs as well. Also included are research articles on long-term community-based results of breast-conserving therapy in early-stage breast cancer, the use of the neurokinin 1 receptor antagonist in moderately emetogenic chemotherapy, risk assessment for hereditary breast and ovarian cancer in minority women, the impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients, and assessing outpatient oncology needs. Finally, Dr Henry examines evolving therapeutic strategies in melanoma.

Listen to the podcast below.

In the June podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses the approval of alectinib as a new option for ALK-positive patients with NSCLC who have progressed on crizotinib, and a How We Do It article in which the authors the implementation of ipilimumab therapy in a private practice oncology group. The authors describe how they addressed start-up and reimbursement issues related to ipilimumab as a model for other expensive new cancer drugs as well. Also included are research articles on long-term community-based results of breast-conserving therapy in early-stage breast cancer, the use of the neurokinin 1 receptor antagonist in moderately emetogenic chemotherapy, risk assessment for hereditary breast and ovarian cancer in minority women, the impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients, and assessing outpatient oncology needs. Finally, Dr Henry examines evolving therapeutic strategies in melanoma.

Listen to the podcast below.

In the June podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses the approval of alectinib as a new option for ALK-positive patients with NSCLC who have progressed on crizotinib, and a How We Do It article in which the authors the implementation of ipilimumab therapy in a private practice oncology group. The authors describe how they addressed start-up and reimbursement issues related to ipilimumab as a model for other expensive new cancer drugs as well. Also included are research articles on long-term community-based results of breast-conserving therapy in early-stage breast cancer, the use of the neurokinin 1 receptor antagonist in moderately emetogenic chemotherapy, risk assessment for hereditary breast and ovarian cancer in minority women, the impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients, and assessing outpatient oncology needs. Finally, Dr Henry examines evolving therapeutic strategies in melanoma.

Listen to the podcast below.

For the May podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights original reports on the prognostic significance of HPV status in postoperative squamous cell carcinoma of the head and neck, the contributions of caregivers in American Indian cancer patients, and the omission of dexamethasone from antiemetics treatment in breast cancer patients with hepatitis B infection or diabetes. He also describes how providers at a comprehensive cancer center devised a framework for implementing survivorship care planning, and, in keeping with the ‘how we do it’ theme, he discusses an article by 2 practicing on oncologists on managing and treating multiple myeloma. The line-up is rounded off with articles on the effects of exercise interventions during different treatments in patients with breast cancer, the approval of trabectedin for some forms of advanced soft tissue sarcoma, and a Case Report on a rare case of hypoglycemia induced by a classical gastro-intestinal stromal tumor.

Listen to the podcast below.

For the May podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights original reports on the prognostic significance of HPV status in postoperative squamous cell carcinoma of the head and neck, the contributions of caregivers in American Indian cancer patients, and the omission of dexamethasone from antiemetics treatment in breast cancer patients with hepatitis B infection or diabetes. He also describes how providers at a comprehensive cancer center devised a framework for implementing survivorship care planning, and, in keeping with the ‘how we do it’ theme, he discusses an article by 2 practicing on oncologists on managing and treating multiple myeloma. The line-up is rounded off with articles on the effects of exercise interventions during different treatments in patients with breast cancer, the approval of trabectedin for some forms of advanced soft tissue sarcoma, and a Case Report on a rare case of hypoglycemia induced by a classical gastro-intestinal stromal tumor.

Listen to the podcast below.

For the May podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights original reports on the prognostic significance of HPV status in postoperative squamous cell carcinoma of the head and neck, the contributions of caregivers in American Indian cancer patients, and the omission of dexamethasone from antiemetics treatment in breast cancer patients with hepatitis B infection or diabetes. He also describes how providers at a comprehensive cancer center devised a framework for implementing survivorship care planning, and, in keeping with the ‘how we do it’ theme, he discusses an article by 2 practicing on oncologists on managing and treating multiple myeloma. The line-up is rounded off with articles on the effects of exercise interventions during different treatments in patients with breast cancer, the approval of trabectedin for some forms of advanced soft tissue sarcoma, and a Case Report on a rare case of hypoglycemia induced by a classical gastro-intestinal stromal tumor.

Listen to the podcast below.

In his April podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses Original Reports on olanzapine compared with fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting and an analysis of patient-reported outcomes in prostate cancer after treatment with abiraterone acetate. Also among the line-up of Original Reports are studies looking at the diagnostic work-up for the detection of malnutrition in hospitalized cancer patients and at the use of video-conferencing to deliver cancer genetic counseling to high-risk underserved individuals. The Case Reports include an unusual case of non-small-cell lung cancer presenting as spontaneous cardiac tamponade, another of severe eosinophilia associated with cholangiocarcinoma, and a third on acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. The Community Translations column features approvals of nivolumab approval for metastatic renal-cell carcinoma. Dr Henry also discusses a feature article on new therapies for multiple myeloma that are redefining the condition as a chronic disease.

Listen to the podcast below.

In his April podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses Original Reports on olanzapine compared with fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting and an analysis of patient-reported outcomes in prostate cancer after treatment with abiraterone acetate. Also among the line-up of Original Reports are studies looking at the diagnostic work-up for the detection of malnutrition in hospitalized cancer patients and at the use of video-conferencing to deliver cancer genetic counseling to high-risk underserved individuals. The Case Reports include an unusual case of non-small-cell lung cancer presenting as spontaneous cardiac tamponade, another of severe eosinophilia associated with cholangiocarcinoma, and a third on acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. The Community Translations column features approvals of nivolumab approval for metastatic renal-cell carcinoma. Dr Henry also discusses a feature article on new therapies for multiple myeloma that are redefining the condition as a chronic disease.

Listen to the podcast below.

In his April podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry discusses Original Reports on olanzapine compared with fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting and an analysis of patient-reported outcomes in prostate cancer after treatment with abiraterone acetate. Also among the line-up of Original Reports are studies looking at the diagnostic work-up for the detection of malnutrition in hospitalized cancer patients and at the use of video-conferencing to deliver cancer genetic counseling to high-risk underserved individuals. The Case Reports include an unusual case of non-small-cell lung cancer presenting as spontaneous cardiac tamponade, another of severe eosinophilia associated with cholangiocarcinoma, and a third on acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. The Community Translations column features approvals of nivolumab approval for metastatic renal-cell carcinoma. Dr Henry also discusses a feature article on new therapies for multiple myeloma that are redefining the condition as a chronic disease.

Listen to the podcast below.